Opus Genetics, Inc.
IRD
$4.03
-$0.04-0.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.98M | 14.20M | 14.63M | 15.42M | 13.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.98M | 14.20M | 14.63M | 15.42M | 13.65M |
| Cost of Revenue | 33.34M | 30.71M | 27.32M | 29.89M | 29.96M |
| Gross Profit | -21.35M | -16.52M | -12.69M | -14.47M | -16.30M |
| SG&A Expenses | 21.68M | 22.08M | 24.49M | 22.40M | 19.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.02M | 52.80M | 51.81M | 52.29M | 49.95M |
| Operating Income | -43.03M | -38.60M | -37.18M | -36.87M | -36.30M |
| Income Before Tax | -106.93M | -49.59M | -68.20M | -58.28M | -58.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -106.93 | -49.59 | -68.20 | -58.28 | -58.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -106.93M | -49.59M | -68.20M | -58.28M | -58.62M |
| EBIT | -43.03M | -38.60M | -37.18M | -36.87M | -36.30M |
| EBITDA | -42.98M | -38.55M | -37.13M | -36.84M | -36.28M |
| EPS Basic | -1.32 | -0.81 | -1.76 | -1.80 | -1.99 |
| Normalized Basic EPS | -0.83 | -0.51 | -0.53 | -0.55 | -0.67 |
| EPS Diluted | -1.32 | -0.81 | -1.76 | -1.80 | -1.99 |
| Normalized Diluted EPS | -0.83 | -0.51 | -0.53 | -0.55 | -0.67 |
| Average Basic Shares Outstanding | 301.49M | 248.48M | 198.26M | 153.77M | 116.22M |
| Average Diluted Shares Outstanding | 301.49M | 248.48M | 198.26M | 153.77M | 116.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |